Anebulo Pharmaceuticals to Acquire Neuro-Bio Ltd. for $10M
Ticker: ANEB · Form: 8-K · Filed: Feb 12, 2025 · CIK: 1815974
| Field | Detail |
|---|---|
| Company | Anebulo Pharmaceuticals, Inc. (ANEB) |
| Form Type | 8-K |
| Filed Date | Feb 12, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, pharmaceuticals
TL;DR
Anebulo buying Neuro-Bio for $10M, Q1 2025 close.
AI Summary
Anebulo Pharmaceuticals, Inc. announced on February 11, 2025, that it has entered into a definitive agreement to acquire all outstanding equity interests of Neuro-Bio Ltd. for an aggregate purchase price of $10 million. The acquisition is expected to close in the first quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition could significantly expand Anebulo's pipeline and therapeutic focus, potentially leading to new treatment options for neurological disorders.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, regulatory hurdles, and the possibility that the acquired company's assets may not perform as expected.
Key Numbers
- $10.0M — Acquisition Price (Aggregate purchase price for Neuro-Bio Ltd.)
Key Players & Entities
- Anebulo Pharmaceuticals, Inc. (company) — Registrant
- Neuro-Bio Ltd. (company) — Target company for acquisition
- $10 million (dollar_amount) — Aggregate purchase price for acquisition
- February 11, 2025 (date) — Date of definitive agreement
- first quarter of 2025 (date) — Expected closing period for acquisition
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing reports on the "Other Events" of Anebulo Pharmaceuticals, Inc., specifically announcing a definitive agreement to acquire Neuro-Bio Ltd.
What is the total value of the proposed acquisition?
The aggregate purchase price for the acquisition of Neuro-Bio Ltd. is $10 million.
When is the acquisition expected to be completed?
The acquisition is expected to close in the first quarter of 2025, subject to customary closing conditions.
What is the exact date of the reported event?
The date of the earliest event reported is February 11, 2025.
What is Anebulo Pharmaceuticals, Inc.'s principal executive office address?
Anebulo Pharmaceuticals, Inc.'s principal executive offices are located at 1017 Ranch Road 620 South, Suite 107, Lakeway, TX 78734.
Filing Stats: 816 words · 3 min read · ~3 pages · Grade level 15.2 · Accepted 2025-02-12 07:00:37
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share ANEB The Nasdaq
Filing Documents
- form8-k.htm (8-K) — 39KB
- 0001493152-25-006036.txt ( ) — 210KB
- aneb-20250211.xsd (EX-101.SCH) — 3KB
- aneb-20250211_lab.xml (EX-101.LAB) — 33KB
- aneb-20250211_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANEBULO PHARMACEUTICALS, INC. Date: February 12, 2025 By: /s/ Richard Anthony Cunningham Richard Anthony Cunningham Chief Executive Officer ( Principal Executive Officer )